Here are the DEF 14A proxy statements from Translational Development Acquisition Corp. (TDAC) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TDAC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TDAC filings page.
Translational Development Acquisition Corp. is asking shareholders to approve amendments that extend its deadline to complete a business combination from June 24, 2026, by up to twelve one‑month periods to June 24, 2027. Each extension would require a deposit into the trust account of the lesser of $200,000 or $0.03 per outstanding public share in exchange for a non‑interest bearing promissory note. Shareholders may redeem their public shares for cash in connection with these proposals, subject to a minimum net tangible asset condition of $5,000,001 and a 15% redemption cap per holder group without consent. The proxy also describes a signed Business Combination Agreement with ProLogium Holding Inc., under which Translational Development would merge into ProLogium subsidiaries, with each Class A ordinary share converting into one ProLogium Class A share and warrants becoming ProLogium warrants. Closing of the Proposed Business Combination is conditioned on multiple approvals and an Available Cash amount of at least $250,000,000; if the extension proposals fail and no deal closes within the current window, the SPAC will redeem all public shares and liquidate, leaving the warrants worthless.